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Abstract
Introduction: At present, the problem of pharmacological correction of free radical processess emerges full-blown. The 
aim of the study is an experimental study of the neuroprotective effect of taurine and 3-hydroxypyridine derivatives.
Materials and methods: The study was performed in Wistar rats. The neuroprotective effect of the substances was 
studied in the intracerebral hemorrhage model.
Results and discussion: The administration of the studied substances had a positive effect on the survival of the ani-
mals within the first day (50% of rats died in the control group, 30% – in the Mexidol- and Ethoxidol-treated groups, 
and 20% – in LKhT 3-17-treated group). Within the first day after the surgery, all rats with stroke had severe neurolog-
ical disorders. However, by the 3rd day, the Ethoxidol- and LKhT 3-17-treated rats had a lower neurological deficit. By 
Day 14, all groups of animals treated with the test substances had a lower severity of post-stroke disorders than those 
in the control group, which was evident as a 1.5-time lower McGraw Stroke Index score. LKhT 3-17 substance showed 
the most pronounced neuroprotective effect.
Conclusions: The studied derivatives of taurine and 3-hydroxypyridine have a neuroprotective effect, which is 
manifested in the lower severity of neurological disorders,a more rapid reduction in the signs of neurodegeneration and 
accelerated hemorrhage processes.
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Introduction
Hemorrhagic stroke is a spontaneous intracranial hemor-
rhage caused by the most common vascular diseases of 
the brain, such as essential hypertension, secondary hy-
pertension, vasculitis, etc., and causing 8–15% of all stro-
kes (De Oliveira Manoel et al. 2016). According to the 
Russian Stroke Association (NABI), 40000 intracerebral 
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haemorrhages are registered annually in Russia. Accor-
ding to the disease progression rate, course and outcome 
of the disease, hemorrhagic stroke is the most dramatic of 
all the cerebrovascular processes.
The effused blood leads to compression of the sur-
rounding brain matter, which is accompanied by a de-
crease in local cerebral blood flow in this area and a 
development of secondary ischemic damage (Vella et 
al. 2017). Reduction of the local cerebral blood flow in 
the area around hemorrhage triggers ischemic pathobio-
chemical cascades in the brain matter: changes in the 
glutamate and calcium metabolism, free radical reac-
tions, lipid peroxidation, excessive synthesis of nitric 
oxide, activation of astro- and microglial cell pools, 
and immune changes and local inflammation associated 
with these changes. Fe3+ ions, which are also a powerful 
cellular oxidant, intensify lipid peroxidation and stim-
ulate the formation of a large number of free radicals, 
are responsible for the permanent brain damage (Walsh 
et al. 2000).
Due to the constant increase in the number of patients 
with this pathology, high mortality (50–70% of patients) 
(Skvortsova et al. 2002) and disability rate (about 2/3 of 
patients) (Karpov et al. 2015), the issues of drug support 
for patients with this type of acute cerebrovascular disorder 
remain the most important problem of the modern neurol-
ogy.
Intensive care of patients with hemorrhagic stroke 
is based on the concept of prevention and treatment of 
recurrent ischemic attacks. The basis of the concept is 
the separation of vascular factors that led to the brain 
damage and are directly related to the moment of the 
disease (primary factors) and pathological effects 
which the brain is exposed to in the subsequent period 
(secondary factors). It is fundamental that preventing 
and limiting the influence of the secondary pathologi-
cal factors can significantly improve the outcome of the 
brain diseases.
A pathogenic therapy of the secondary ischemic brain 
damage is aimed at interrupting the reactions of gluta-
mate-calcium cascade as rapid mechanisms of necrotic 
cell death. In this regard, the problem of pharmacological 
correction of the free-radical processes using exogenous 
drugs with antioxidant and antihypoxant effects is becom-
ing relevant (Pohl and Kong Thoo Lin 2018).
The aim of this study was the experimental study of 
the therapeutic effects of taurine and 3-hydroxypyridine 
derivatives with potential neuroprotective effects in the 
intracerebral hemorrhage model (intracerebral posttrau-
matic hematoma) in rats.
Materials and methods
The study was performed in white male Wistar rats weig-
hing 200 to 240g (Basov et al. 2019). Animal care was 
in compliance withthe laboratory practice of preclinical 
studies in the Russian Federation (GOST Z 51000.3-96 
and 51000.4-96) and the Order of the Ministry of Health-
care of the Russian Federation №267 of 19 June 2003 
On	Approval	of	 the	Rules	of	Good	Laboratory	Practice 
(GLP), following the international recommendations of 
the European	Convention	for	the	Protection	of	Vertebral	
Animals	Used	for	Experimental	and	Other	Scientific	Pur-
poses (1997).
The animals were divided into several groups: 
Group 1 – sham operated rats (10 animals), which were 
anesthetized, then scalping and cranial trepanation 
were performed, without destruction of the brain tissue; 
Group 2 – untreated animals with hemorrhagic stroke 
(control group, 20 rats); Groups 3 and 4–animals with 
hemorrhagic stroke, which were treated with Mexidol and 
Ethoxidol, respectively (20 rats in each group); Group 5 – 
animals with simulated pathology, which received LKhT 
3-17 (20 rats).
Aсute autohemorrhagic stroke was simulated in the 
region of the internal capsule of the right hemisphere, 
according to the method by A. N. Makarenko et al. 
(Makarenko et al. 1990) modified for the current study. 
The operation was performed under general anesthesia 
by means of intraperitoneal administration of Xyla at 
a dose of 0.1 ml for premedication; after anxiolysis, 
the rats were administered intraperitoneally with chlo-
ral hydrate at a dose of 300 mg/kg as a basic narcosis. 
Upon deep general anesthesia, blood was sampled with 
a syringe from the tail vein of the rat. Then preoper-
ative showering and a linear incision of the scalp in 
the parietal region were performed. The incision was 
performed in the frontal plane, followed by hemostasis. 
The length of the incision was 1.5 cm. Subsequently, 
skeletization and periosteal separation were performed. 
A burr hole was applied in the right parietal region, 
using a dental bur. The diameter of the burr hole was 
3 mm. Later, using a puncture needle and a special-
ly designed device for stereotactic administration, a 
puncture needle was inserted in the area of the internal 
capsule (coordinates H=4 mm, L=3.0 mm, A=1.5 mm 
from bregma, according to Paxinos’ reference atlas) 
to a depth of 3 mm. Then the device was fixed, and 
a mandrin knife was inserted into the needle, destroy-
ing the brain tissue (the mandrin knife was turned three 
times clockwise and three times counterclockwise). 
The mandrin knife was removed, and then aseptically, 
autologous blood was infused into rats, the blood being 
taken from the tail vein of the animal in the amount of 
0.11 ml/100g of weight. The effectiveness of the ad-
ministration was determined by the presence of stem 
seizures. After that, the puncture needle was removed, 
the wound was drained, hemostasis was controlled, and 
layer-by-layer suturing of the wound was performed. In 
the sham operated animals, scalping and cranial trepa-
nation were performed.
The test drugs were administered to the animals once 
intraperitoneally, 1 hour before surgery. LKhT 3-17 (a de-
rivative of magnesium and bisaminoethansulfonic acid) 
(All-Russian Scientific Center for the Safety of Biolog-
ically Active Substances, Kupavna) was administered at 
a dose of 10 mg/kg (1/100 LD50). Mexidol (Pharmasoft, 
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Russia) and Ethoxidol (Synthesis, Russia) at a dose of 
50 mg/kg each (according to the interspecies conversion 
of the average human dose), used in clinical practice to 
treat cerebrovascular diseases, were selected as the refer-
ence drugs. The control animals were administered with 
saline solution in equivalent volume.
The animals were observed for14 days after the opera-
tion. The behavior and condition of the animals on the 1st, 
3rd, 7th and 14th days were recorded.
To assess disruptions of the behavior and condition of 
the animals after hemorrhagic stroke, a set of traditional 
methods applied for such purposes in the experiment was 
used. To evaluate the neurological status, the neurological 
deficit assessment method according to McGraw Stroke 
Index modified by I.V. Gannushkina (Gannushkina 1996) 
was applied, along with the muscle tone evaluation by 
measuring the grip strength of the animals’ limbs using 
a dynamometer.
When assessing the neurological status according to 
McGraw Stroke Index modified by I.V. Gannushkina, 
the rats were divided into a group with mild symptoms 
(up to 3 points) – sluggish movements, weakness of 
limbs, one-sided hemiptosis, tremor, circus movement 
– and a group with severe manifestations of the neuro-
logical impairment (from 3.5 to 10 points) – paresis and 
paralysis of the limbs, lateral position, and depression of 
consciousness.
Measurement of the animals’ strength in the grasp-
ing test was carried out using a hardware-software com-
plex, designed in the Student Robotics Development 
Laboratory by A.Yu. Aleynikov. The relative value 
(specific force) calculated as the ratio of the maximum 
grip force to the rat body weight was determined as a 
comparison criterion.
The platform for studying the motor activity of labora-
tory animals ACTI-TRACK (Panlab Harvard Apparatus, 
Barcelona, Spain) was used to assess the investigative be-
havior. The rat was tested for 5 minutes by the infrared 
activity monitor before the pathology simulation and then 
on the 1st, 3rd, 7th and 14th days after the simulation of hem-
orrhagic stroke.
For morphological evaluation, the animals were re-
moved from the experiment 24, 72 hours, 7 and 14 days 
after the study start. The rats were decapitated; the brain 
was withdrawn, fixed in 10% neutral buffered formalin 
for 24–48 hours and embedded into paraffin. The fron-
tal histological sections of the brain of 7 µm thick were 
stained with hematoxilin and eosin. A MIKMED-6 micro-
scope with binocular adjustment, backlight illumination, 
a digital camera MS-5 and a computer with MCview soft-
ware were used in the study.
Statistical processing of the obtained data was per-
formed using STATISTICA 10.0 and MICROSOFT EX-
CEL 2016. Descriptive statistics was applied to all data. 
The normality of distribution was assessed by means of 
Shapiro-Wilk and Kolmagorov-Smirnov tests. Statisti-
cal significance depending on the particular data was as-
sessed by using Student’s test and Bonferroni-corrected 
Mann-Whitney tests. Differences at p<0.05 were recog-
nized as statistically significant.
Results and discussion
The influence of the drugs on the survival of the ani-
mals within 1 day
During the operation and within 1 day after it, 50% of 
rats with hemorrhagic stroke died in the control group. 
In the group of animals treated with the studied substan-
ces, mortality within 1 day was lower than in the control 
group. In particular, in the groups of animals treated with 
Mexidol or Ethoxidol, the daily survival rate was 70%. In 
the LKhT 3-17 group, 80% of rats survived. In the group 
of sham operated animals, no deaths were recorded du-
ring the entire observation period.
In the surviving animals with hemorrhagic stroke, var-
ious neurological and behavioral disorders were subse-
quently recorded.
The influence of the drugs on the МсGraw Stroke In-
dex score of neurologic deficit after the stroke
Within the first day after the operation, neurological di-
sorders in almost all rats with simulated intracerebral he-
matoma were observed in the form of fatigue and slow 
movements, whereas in the sham operated rats, these 
disorders were observed in 30% of individuals. No pro-
nounced neurologic deficit, manifested in the form of cir-
cus movements and limb paralysis was observed in the 
group of the sham operated animals, but it was noted in 
100% of animals with hemorrhagic stroke.
Throughout days 1–7, the rats treated with Mexidol did 
not have any significant differences in the McGraw Stroke 
Index score with the control group, whereas the animals 
treated with Ethoxidol and LKhT 3-17 had statistically sig-
nificantly less pronounced neurologic deficit throughout the 
entire observation period. However, by the 14th day, all the 
animals receiving the studied substances had more than 1.5-
time lower McGraw Stroke Index score than in the control 
group. There were no significant differences in the severity 
of neurologic deficit on the 14th day in the groups of rats 
with simulated pathology, receiving different substances.
The influence of the studied drugs on the grip strength 
of the rats after stroke in the dynamometer test
The registration of the grip strength in the rats with he-
morrhagic stroke showed that on the first day after stroke, 
loss of the muscle tone in the control group and in the 
Mexidol group did not differ significantly and averaged 
58.2% (Table 1). In the groups treated with Ethoxidol and 
LKhT 3-17, the average decrease in the muscle tone on 
the 1st day was 37.2%, which was significantly lower than 
in the control group.
There was an increase in muscle strength in all groups 
on the 3rd day, and in the groups receiving the studied sub-
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stances, an increase was significantly higher than in the 
control group. On the 7th and 14th days, a statistically sig-
nificant increase in the muscle strength was recorded only 
in the group treated with LKhT 3-17.
The influence of the studied drugs on the motor activi-
ty of the animals with hemorrhagic stroke
During the entire observation period (1–14 days) after 
the hemorrhagic stroke simulation, the indices of total 
activity, stereotype of movements, locomotor activity, 
maximum speed, average speed, total distance under the 
influence of Ethoxidol and LKhT 3-17 were significantly 
higher than those in the control group (Table 2).
The motor scores of the rats treated with Mexidol on 
the 1st, 3rd and 7th days were significantly inferior to the 
results of the animals treated with Ethoxidol and LKhT 
3-17, and on the 1st and 3rd days after surgery, they had 
no significant differences from those of the control group. 
However, the motor activity of the animals treated with 
Mexidol increased by the 14th day and had no statistical-
ly significant differences from those of the groups treated 
with the other studied substances.
LKhT 3-17 substance increased the motor score most 
on the 1st and 3rd days in comparison with other groups.
The high motor scores of the control group on the 14th 
day can be explained by high mortality in this group, in 
which only the strongest animals with high regenerative 
potential survived.
The results of the morphological study of the brain
In the control group during the 1-3 days after hemorrhage, 
there was perivascular and pericellular edema in the narrow 
Table 1. Influence of Mexidol, Ethoxidol and LKhT 3-17 on the 
Indicators of Neurological Status on the 1st, 3rd, 7th and 14th Days 
after Hemorrhagic Stroke Simulation.
Before pathology simulation
Control Mexidol Ethoxidol LKhT 3-17
Specific force 6.7±0.2 7.4±0.3* 6.0±0.4* 6.1±0.3*
McGraw 0 0 0 0
1st day
Control Mexidol Ethoxidol LKhT 3-17
Specific force 2.8±0.2 3.1±0.1 3.7±0.3* 3.9±0.3*
McGraw 8.1±2.0 7.0±2.2 6.7±2.4* 5.8±2.3*
3rd day
Control Mexidol Ethoxidol LKhT 3-17
Specific force 3.6±0,4 5.0±0.2* 4.6±0.5* 4.6±0.5*
McGraw 5.8±1.7 5.2±2.1 4.3±1.8* 4.2±1.7*
7th day
Control Mexidol Ethoxidol LKhT 3-17
Specific force 4.2±0.4 4.5±0.5 4.52±0,3 5.0±0.6*
McGraw 5.4±2.0 4.7±1.8 3.6±1.9* 3.7±1.8*
14th day
Control Mexidol Ethoxidol LKhT 3-17
Specific force 4.90±0.3 4.8±0.4 5.15±0.5 5.7±0.6*
McGraw 5.1±2.2 3.3±0.3* 3.2±0.4* 3.1±0.3*
Note: * – p<0.05 – the differences are statistically significant in 
comparison with the control group of animals.
Table 2. Influence of Mexidol, Ethoxidol and LKhT 3-17 on the 
Ethological Indicators Calculated by Using ActiTrack Software on 
the 1st, 3rd, 7th and 14th Days after Hemorrhagic Stroke Simulation.
Before pathology simulation
Control Mexidol Ethoxidol LKhT 3-17
Total activity 1010±76 1188±49 1177±44 1139±46
Stereotype of 
movements
27±3 29±1 28±1 30±1
Locomotor 
activity
983±74 1036±51 986±34 1016±34
Maximum speed 22±1 22±1 22±1 23±1
Average speed 1.8±0.1 2.2±0.3 2.2±0.3 1.9±0.2
Total distance 545±43 594±24 557±24 557±29
1st day
Control Mexidol Ethoxidol LKhT 3-17
Total activity 495±74 407±47 680±86* 941±192*
Stereotype of 
movements
40±4 39±7 58±9* 73±14*
Locomotor 
activity
422±35 369±40* 622±78* 868±178*
Maximum speed 21±2 16±2* 29±2* 30±4*
Average speed 2.0±1.0 1.7±0.0* 3.9±0.6* 6.5±1.0*
Total distance 610±77 520±78* 1160±193* 1930±545*
3rd day
Control Mexidol Ethoxidol LKhT 3-17
Total activity 580±136 658±99 1092±102* 1704±788*
Stereotype of 
movements
18±6 61±10* 83±8* 70±8*
Locomotor 
activity
661±137 597±89 1009±95* 801±123
Maximum speed 14±1 28±2* 34±2* 34±4*
Average speed 1±0 3.8±0.6* 7.1±0.9* 5.9±1.4*
Total distance 276±51 1128±181* 2132±271* 1721±402*
7th day
Control Mexidol Ethoxidol LKhT 3-17
Total activity 431±91 689±115* 1016±146* 858±142*
Stereotype of 
movements
20±8 64±12* 82±16* 67±15*
Locomotor 
activity
411±88 625±104* 934±131* 792±130*
Maximum speed 19±3 27±3* 35±3* 31±1*
Average speed 1±0.3 4±0.8* 6.6±1* 5.1±1.2*
Total distance 304±82 1198±226* 1940±297* 1524±353*
14th day
Control Mexidol Ethoxidol LKhT 3-17
Total activity 1133±90 829±43* 807±144* 874±155*
Stereotype of 
movements
69±9 86±7* 68±14 76±6
Locomotor 
activity
1097±92 749±36* 739±132* 770±166*
Maximum speed 19±2 34±4* 33±2* 32±5*
Average speed 2.0±0.2 5.1±0.5* 5±1* 5.5±1.7*
Total distance 586±65 1524±159* 1503±290* 1393±65*
Note: * – p<0.05 – the differences are significant in comparison 
with the control group of animals.
Research Results in Pharmacology 5(3): 87–94 91
zone (0.5–1.0 mm), surrounding the hematoma; disrupted 
cytoarchitectonics of six layers of cortical neurons, pron-
ounced ischemic changes, karyolysis of neurons; there was 
also a pronounced perifocal leukocytic reaction and a less 
pronounced glial reaction. Cerebral edema was accompan-
ied by a number of successive morphological changes in the 
vascular wall and microcirculatory bloodstream (Table 3). 
At first, there was spasm of the arterioles, followed by their 
emptying of blood. By day 3 after hemorrhage, this conditi-
on was replaced by paretic dilatation of capillaries, arterioles 
and venules. In the lumen of the vessels during this period, 
there was the accumulation and margination of blood cor-
puscles, in particular leukocytes (Fig. 1). Dilated perivascu-
lar spaces filled with plasma indicated a significantly incre-
ased permeability of the vascular wall, leading to secondary 
diapedetic perivascular hemorrhages.
Starting from the 7th day, the pronounced perifocal 
leukocytic reaction gave way to a pronounced glial mac-
rophage reaction; there started to aappear macrophage 
clumping with intracellular accumulation of a blood pig-
ment (hemosiderophages) (Fig. 2).
Subsequently, by the 14th day, the regenerative process-
es of the glial cells led to the formation of a thin capsule 
around the hemorrhage site with aggregates of single he-
mosiderophages and blood pigment (Fig. 3).
The analysis of the LKhT 3-17 group revealed that 
perifocal edema was decreasing more quickly in compari-
son with the control group and other experimental groups 
(Mexidol, Ethoxidol) and almost completely disappeared 
by the 7th day. In the animals treated with LKhT 3-17, the 
signs of the inflammatory reaction with the development 
of neutrophil infiltration were more pronounced (Ta-
ble 3). At the same time, the severity of the inflammatory 
reaction did not reach the intensity of that in the control 
group. Within the same period of time, similar changes 
were observed in the microcirculatory bloodstream (Ta-
ble 3). Then, starting from the 3rd day and up to the end of 
the observation, against the background of more active re-
generative processes, the stabilization processes of micro-
circulatory disorders proceeded more rapidly, and the se-
verity of the microcirculatory bloodstream disorders was 
decreasing much more quickly than in the control group 
and a bit more quickly than the other experimental groups 
(Mexidol, Ethoxidol) (Table 3). This was accompanied by 
less pronounced damage to neurons and glial cells, ac-
celerated processes of resorption and organization of the 
lesion, especially after the 3rd day of the disease (Table 3).
The results of the study confirm a neuroprotective ac-
tion of all the studied substances. However, the neuropro-
tective activity of Mexidol developed more slowly – by the 
14th day, unlike Ethoxidol and LKhT 3-17, which showed 
their cerebroprotective activity as early as on the 1st day 
Figure 1. Neuronal degeneration of the brain in the hematoma 
area in rats of the control group on the 3rd day. Hematoxylin and 
eosin stain. ×100.
Table 3. Dynamics of the Morphological Changes in the Rat 
Brain Under the Influence of Mexidol, Ethoxidol and LKhT 
3-17 on the 1st, 3rd, 7th and 14th Days after Hemorrhagic Stroke 
Simulation.
Groups 1st–3rd days 7th day 14th day
Microcirculatory disorders
Control + +++ ++
Mexidol +/++ ++ +
Ethoxidol ++/+++ +/++ +
LKhT 3-17 +++ +/++ +
Changes of neurons
Control +++ ++ +
Mexidol ++/+++ +/++ -
Ethoxidol ++ + -
LKhT 3-17 +/++ + -
Glial reaction
Control +++ ++/+++ ++
Mexidol ++/+++ ++ +/++
Ethoxidol ++/+++ +/++ +
LKhT 3-17 ++ +/++ +
Neutrophil infiltration
Control +++ ++/+++ ++
Mexidol ++ ++ +
Ethoxidol ++ +/++ +
LKhT 3-17 ++/+++ + -
Macrophage infiltration
Control + +/++ ++
Mexidol ++/+++ ++ +/++
Ethoxidol ++/+++ ++/+++ +/++
LKhT 3-17 ++/+++ +++ +/++
Hemosiderophage infiltration
Control - + ++
Mexidol - +/++ ++
Ethoxidol - ++ +/++
LKhT 3-17 - +++ +/++
Blood pigment
Control - - +
Mexidol - + ++
Ethoxidol - + ++
LKhT 3-17 - +/++ +++
Note: the severity of morphological changes range from + to 
+++, where + – means minimal morphological changes; +++ – 
maximum morphological changes.
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(less severe neurological disorders and higher activity of 
the animals of these groups in the infrared monitor).
LKhT 3-17 has a more pronounced neuroprotective 
activity, which is manifested by a significant decrease in 
the severity of post-stroke disorders. These differences 
are especially noticeable by the 3rd day of the disease, 
which is confirmed by a 1.5-time higher activity of the 
animals of this group compared to those in the Ethoxidol 
group,by almost a 3-time higher activity compared to 
that of the control; as well as by histological examina-
tion of the brain sections. According to the histological 
study, LKhT 3-17 administration is accompanied by a 
decrease in perifocal edema and microcirculation disor-
ders within a shorter period of time, less damage to neu-
rons and glial cells and faster processes of hemorrhage 
resorption and organization.
A high neuroprotective activity of LKhT 3-17 sub-
stance is probably due to its chemical structure, as it is a 
derivative of magnesium and bisaminoethansulfonic acid.
The presence of magnesium ion in the structure of the 
substance provides its antioxidant (Shahmardanova et al. 
2016) and membrane trophic activities. Magnesium ions 
block NMDA channels in a voltage-dependent manner, 
preventing the development of a complex of glutamate 
excitotoxicity reactions (Muir et al. 2004).
Bisaminoethansulfonic acid residue, a derivative of 
taurine, provides neuroregenerative properties. The pro-
tective action of taurine in relation to stroke and athero-
sclerotic lesions of the arteries were convincingly shown 
in the experiments (Yamori et al. 1996, Yamori et al. 
2001, Yamori et al. 2009).
Taurine is one of the five quantitatively predominant 
amino acids in the brain and is called “brain growth fac-
tor” (Chen et al. 1998). Taurine influences cell migration, 
modulates synaptic neurotransmission and can accelerate 
brain development, (at an extracellular concentration of 
10 mM), attenuates the release of dopamine and its me-
tabolites caused by over-activation of NMDA receptors, 
thus preventing neuronal death (Sato et al. 1991).
Figure 2. Neuronal degeneration of the brain in the hematoma area in rats of the control group on the 7th day. Hematoxylin and eosin 
stain. A:×100; B:×400.
A B
Figure 3. Neuroregenerative processes of the brain in the hematoma area in rats of the control group on the 14th day. Hematoxylin 
and eosin stain. A:×100; B:×400.
A B
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The ability to regulate the concentration of intracel-
lular calcium is one of the most important properties of 
taurine (Schaffer and Kim 2018). It is known that gluta-
mate causes a rapid increase in the concentration of free 
Ca2+ ions in the cytoplasm, which leads to the collapse 
of the mitochondrial electrochemical gradient and sub-
sequent cell death. Not only does taurine reduce the in-
tensity of Ca2+ output, but also contributes to the rapid 
return of these ions to their original state, which is one of 
the mechanisms for preventing or reducing the glutamate 
neurotoxicity (Ripps and Shen 2012).
One of the factors of cell damage is the membrane 
integrity breach, followed by an inflow of water and os-
motic ions. This leads to cell swelling and subsequent 
negative effects. There is sufficient evidence about the 
role of taurine as an active osmoregulator, which is es-
pecially important for brain neurons (Terrill et al. 2017, 
McCarty 2017).
The obtained results showed the possibility of a further 
study of taurine derivatives, in particular, the substance 
under code LKhT 3-17 as neuroprotective drugs, and 
their future practical application in clinical practice for 
the treatment and prevention of cerebrovascular diseases.
Conclusion
1. The studied derivatives of taurine and 3-hydroxypyri-
dine have a neuroprotective effect, which is manifest-
ed in less severe neurological disorders, a more rapid 
decrease in the signs of neurodegeneration, and accel-
erated processes of the hemorrhage organization.
2. A neuroprotective activity of Mexidol developed 
more slowly – by the 14th day, unlike Etxydol and 
LKhT 3-17 which showed their cerebroprotective 
activity on the 1st day.
3. LKhT 3-17 has a more pronounced neuroprotective 
activity, which is manifested by a significant de-
crease in the severity of post-stroke disorders. These 
differences are especially noticeable by the 3rd day 
of the disease, which is confirmed by the higher 
activity of the animals of this group, as well as by 
the histological examination of the brain sections – 
a more rapid decrease in the perifocal edema and 
microcirculation disorders, less damage to neurons 
and glial cells, and faster processes of the hemor-
rhage resorption and organization.
Conflict of interests
The authors state no conflict of interest concerning with 
the present submitted manuscript.
References
  Basov A, Fedulova L, Baryshev M, Dzhimak S (2019) Deuteri-
um-depleted water influence on the isotope 2H/1H regulation in 
body and individual adaptation. Nutrients 11(8): E1903. https://doi.
org/10.3390/nu11081903 [PubMed] [PMC]
  Chen XC, Pan ZL, Liu DS, Han X (1998) Effect of taurine on human 
fetal neuron cells: proliferation and differentiation. In: Schaffer S, 
Lombardini JB, Huxtable RJ (Eds) Taurine 3. Advances in Experi-
mental Medicine and Biology, Springer, Boston, MA, vol. 442, pp. 
397–403. https://doi.org/10.1007/978-1-4899-0117-0_49 [PubMed]
  De Oliveira Manoel AL, Goffi A, Zampieri FG, Turkel-Parrella D, 
Duggal A, Marotta TR, Macdonald RL, Abrahamson S (2016) The 
critical care management of spontaneous intracranial hemorrhage: a 
contemporary review. Critical Сare 20: 272. https://doi.org/10.1186/
s13054-016-1432-0 [PubMed] [PMC]
  Gannushkina IV (1996) Pathomorphological mechanisms of cere-
bral circulation disorders and new developments in their prevention 
and treatment. S.S. Korsakov Journal of Neurology and Psychiatry 
[Zhurnal Nevropatologii i Psikhiatrii im. S.S. Korsakova] 1: 14–18. 
[in Russian]
  Karpov SM, Dolgova IN, Vishlova IA (2015) The Main Issues of 
Topical Diagnosis of Nervous System Diseases. Stavropol, SSMU, 
68 pp. [in Russian]
  Makarenko AN, Kositsyn NS, Karpenko SV, Mishina VA (1990) In-
ventor’s certificate № 1767518 of 03.11.1990. [in Russian]
  McCarty MF (2017) Supplementation with phycocyanobilin, ci-
trulline, taurine, and supranutritional doses of folic acid and bio-
tin-potential for preventing or slowing the progression of diabetic 
complications. Healthcare 5(1): E15. https://doi.org/10.3390/health-
care5010015 [PubMed] [PMC]
  Muir KW, Lees KR, Ford I, Davis S (2004) Intravenous mag-
nesium efficacy in stroke (IMAGES) study investigators. 
Lancet 363(9407): 439–445. https://doi.org/10.1016/S0140-
6736(04)15490-1 [PubMed]
  Pohl F, Kong Thoo Lin P (2018) The potential use of plant natu-
ral products and plant extracts with antioxidant properties for the 
prevention/treatment of neurodegenerative diseases: in vitro, in vivo 
and clinical trials. Molecules 23(12): E3283. https://doi.org/10.3390/
molecules23123283 [PubMed] [PMC]
  Ripps H, Shen W (2012) Review: taurine: a “very essential” amino 
acid. Molecular Vision 18: 2673–2686. [PubMed] [PMC]
  Sato Y, Ogata E, Fujita T (1991) Hypotensive action of taurine in 
DOCA-salt rats — involvement of sympathoadrenal inhibition and 
endogenous opiate. Japanese Circulation Journal 55(5): 500–508. 
https://doi.org/10.1253/jcj.55.500 [PubMed]
  Schaffer S, Kim HW (2018) Effects and mechanisms of taurine as a 
therapeutic agent. Biomolecules and Therapeutics 26(3): 225–241. 
https://doi.org/10.4062/biomolther.2017.251 [PubMed] [PMC]
  Shahmardanova SA, Gulevskaya ON, Galenko-Yaroshevsky PA, 
Kolesnichenko PD (2016) Development perspectives of new gen-
eration medications based on the redox system regulators. Research 
Result: Pharmacology and Clinical Pharmacology 2(4): 95–102.
  Skvortsova VI, Chazov IE, Stakhovskaya LV (2002) Secondary Pre-
vention of a Stroke. PAGRI, Moscow, 120 pp. [in Russian]
Nesterova NI et al.: Neuroprotective effects of  taurine and 3-hydroxypyridine derivatives94
  Terrill JR, Pinniger GJ, Nair KV, Grounds MD, Arthur PG (2017) 
Beneficial effects of high dose taurine treatment in juvenile dys-
trophic mdx mice are offset by growth restriction. PLoS One 
12(11): e0187317. https://doi.org/10.1371/journal.pone.0187317 
[PubMed] [PMC]
  Vella MA, Crandall ML, Patel MB (2017) Acute management of trau-
matic brain injury. The Surgical Clinics of North America 97(5): 1015–
1030. https://doi.org/10.1016/j.suc.2017.06.003 [PubMed] [PMC]
  Walsh K, Smith RC, Kim HS (2000) Vascular cell apoptosis in 
remodeling, restenosis, and plaque rupture. Circulation Research 
87(3): 184–188. https://doi.org/10.1161/01.RES.87.3.184 [PubMed]
  Yamori Y, Liu L, Ikeda K, Miura A, Mizushima S, Miki T, Nara 
Y (2001) Distribution of twenty-four hour urinary taurine excretion 
and association with ischemic heart disease mortality in 24 popu-
lations of 16 countries: result from the WHO – CARDIAC study. 
Hypertension Research 24(4): 453–457. https://doi.org/10.1291/
hypres.24.453 [PubMed]
  Yamori Y, Liu L, Mori M, Sagara M, Murakami S, Nara Y, Mizushi-
ma S (2009) Taurine as the ulfonamide factor for the longevity of the 
Japanese revealed by a world-wide epidemiological survey. In: Azu-
ma J, Schaffer SW, Ito T (eds) Taurine 7. Advances in Experimental 
Medicine and Biology, vol 643. Springer, New York, NY. https://doi.
org/10.1007/978-0-387-75681-3_2 [PubMed]
  Yamori Y, Nara Y, Ikeda K, Mizushima S (1996) Is taurine a pre-
ventive nutritional factor of cardiovascular diseases or just a bio-
logical marker of nutrition? In: Huxtable RJ, Azuma J, Kuriyama 
K, Nakagawa M, Baba A (eds) Taurine 2. Advances in Experimental 
Medicine and Biology, vol 403. Springer, Boston, MA. https://doi.
org/10.1007/978-1-4899-0182-8_69
Author contributions
  Natalia I. Nesterova, postgraduate student; e-mail: sushkova-nesterova@mail.ru. The author performed a histo-
logical study, as well as an assessment of the neurological status of the animals.
  Olesya V. Shcheblykina, postgraduate student; e-mail: sheolvi31@gmail.com. The author conducted the analysis 
and interpretation of the results.
  Pavel D. Kolesnichenko, PhD in Medical Sciences, Associate Professor; e-mail: farpavel@yandex.ru. The author 
designed the experimental part and was directly engaged in performing the experiment.
  Arkady V. Nesterov, PhD in Medical Sciences, Associate Professor; e-mail: nesterov_a@yandex.ru. The author 
took part in the development of a pathology simulation and directly performed it.
  Dmitry V. Shcheblykin, postgraduate student; e-mail: dmitryshch1@gmail.com. The author took part in the anal-
ysis of the clinical material, results and conclusions.
  Irina A. Popova, student; e-mail: popova.irina-alexandrovna@yandex.ru. The author analyzed and designed the 
list of references.
  Dmitry V. Yakovlev, postgraduate student; e-mail: postmanwestern@gmail.com. The author was engaged in the 
design of the article and statistical processing of the material.
